We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

SVT:LSESevern Trent Plc Analysis

Data as of 2026-05-19 - not real-time

£3,012.00

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Severn Trent trades at 3,012 p, comfortably above its 20‑day (3,113.55 p) and 50‑day (3,111.55 p) SMAs but still below the 200‑day SMA (2,860.02 p), indicating a short‑term pull‑back within a longer‑term uptrend. The 14‑day RSI sits at 44, suggesting neutral momentum, while the MACD line is deep in bearish territory (-34.1) with a bearish signal line (-10.5), flagging potential downside pressure. Volume is decreasing and 30‑day volatility is high at 39 %, yet the beta is extremely low (≈0.03), underscoring the stock’s defensive nature. Fundamental metrics show a trailing PE of 28.7 versus an industry average of 21.4, a forward PE of 14.9, and a DCF‑derived fair value of 3,303 p, implying a modest upside of about 6.7 % from current levels. The dividend yield remains attractive at 4.2 % but the payout ratio exceeds 100 %, raising concerns about sustainability. Recent news highlights a 4‑5 % sell‑off tied to domestic political instability and broader inflationary pressures, which has pressured the share price despite the underlying regulated business model.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bearish MACD and recent political‑driven sell‑off
  • Neutral RSI and decreasing volume
  • Price still above key support at 2,844 p

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • DCF fair value suggests ~7 % upside
  • Strong revenue growth (18 %) and solid operating margins
  • Regulated utility model provides stable cash flows

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Long‑term defensive sector with low beta
  • High dividend yield but unsustainable payout ratio
  • Potential regulatory changes and political risk in the UK

Key Metrics & Analysis

Financial Health

Revenue Growth18.00%
Profit Margin11.92%
P/E Ratio28.7
ROE17.41%
ROA2.91%
Debt/Equity596.74
P/B Ratio5.0
Op. Cash Flow£1.0B
Free Cash Flow£-970550016
Industry P/E21.4

Technical Analysis

TrendBullish
RSI44.0
Support£2,844.00
Resistance£3,335.00
MA 20£3,113.55
MA 50£3,111.55
MA 200£2,860.02
MACDBearish
VolumeDecreasing
Fear & Greed Index89.29

Valuation

Fair Value£3,302.94
Target Price£3,214.23
Upside/Downside6.71%
GradeUndervalued
TypeBlend
Dividend Yield4.20%

Risk Assessment

Beta0.02
Volatility39.22%
Sector RiskLow
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.